DLX2 and primary central nervous system lymphoma: Therefore, these results suggest that small molecule or peptide inhibitors that block TES1 signaling may have therapeutic benefit, even in the absence of effects on TES2, for instance, in the setting of EBV-driven post-transplant and central nervous system lymphomas, which frequently express the latency III program and which are modeled by LCLs.